Αποτελέσματα Αναζήτησης
10 Ιουλ 2024 · New HIV drug can only offer hope of ending AIDS if all have access, UNAIDS says. GENEVA, 10 July 2024— UNAIDS has welcomed the release of Gilead Sciences’ trial results on the injectable long-acting HIV medicine Lenacapavir for HIV prevention.
6 Μαρ 2024 · A once-daily oral combination therapy for HIV — bictegravir plus lenacapavir — is more effective than complex regimens are, according to results from a phase 2 study of people with HIV who are virologically suppressed, presented the Conference on Retrovirus and Opportunistic Infections (CROI) in Denver.
4 Ιαν 2023 · Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.
14 Μαρ 2023 · At the Conference on Retroviruses and Opportunistic Infections (CROI 2023) in February, many researchers presented studies looking at new drugs being tested for use as treatment, pre-exposure prophylaxis (PrEP), and post-exposure prophylaxis (PEP). Here are some highlights.
1 Σεπ 2023 · Lenacapavir, an injection, has been approved by the FDA for multi-drug resistant HIV. HIV is not curable yet, but it can be treated successfully throughout someone's lifespan.
23 Δεκ 2021 · The Food and Drug Administration has approved the first injectable medication for HIV prevention. Health advocates say it could be a game changer in protecting people against AIDS
17 Απρ 2024 · New regimens in development, including once-weekly pills and semiannual shots, could help control the virus in hard-to-reach populations.
